Petra Capital Research Report | June 2024

14 June 2024
14 June 2024 Orthocell

Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.

Following last week’s announcement that Orthocell has applied to the TGA for Australian market approval for its SmrtGraft™ tendon repair device, the report forecasts Orthocell’s potential to reach A$1.28 per share.

“OCC’s SmrtGraft™ tendon product application for approval in Australia opens up a potential third product revenue stream for the CelGro™ platform and is currently not in our forecasts. For use by Orthopaedic surgeons, we see distribution as well as manufacturing synergies with OCC’s Remplir nerve product. As such, it represents a potential attractive revenue stream without much additional cost. With OCC on track for US approval of Remplir in 1QCY25, our TP of $1.28/sh offers >3x upside.”

Click here to read the research report.